Skip to main content
Bioverativ's IND for sickle cell disease drug accepted by FDA

The FDA accepted Bioverativ's investigative new drug application for BIVV003 as a treatment for sickle cell disease. The acceptance of the IND allows the company to launch a Phase I/II study to evaluate the safety of the candidate in adult patients with the disease.

Full Story: